Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC

Author:

Yang Jiwon1ORCID,Choi Jonggi1ORCID,Choi Won‐Mook1ORCID,Kim Kang Mo1ORCID,Lee Han Chu1ORCID,Shim Ju Hyun1ORCID

Affiliation:

1. Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

Abstract

AbstractBackground & AimsTumour microenvironment heterogeneity among different organs can influence immunotherapy responses. Here, we evaluated the impact of differential organ‐specific responses on survival in patients with advanced‐stage hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev).MethodsWe retrospectively analysed 366 consecutive patients with advanced‐stage HCC treated with Atezo/Bev as first‐line systemic treatment. Therapeutic response was assessed using RECIST v1.1. Patients were divided into an intention‐to‐treat (ITT) group (patients treated with ≥1 dose of Atezo/Bev) and a per‐protocol (PP) analysis group (patients with at least one measurable lesion irrespective of location treated with ≥3 doses of Atezo/Bev). Overall response and organ‐specific response at initial and best response were evaluated in the PP group. Responders were defined as patients achieving complete remission or partial response. Initial progressors were defined as patients with progressive disease after three doses of Atezo/Bev.ResultsThe ITT and PP groups comprised 324 and 236 patients, respectively. In the PP group, the organ‐specific response rate of lung and lymph node (LN) metastases at both initial and best responses were higher than those of intrahepatic lesions and macrovascular tumour thrombosis. Lung and LN‐specific response rates were 21.1% and 23.5%, respectively, at initial response, and 24.7% and 31.4%, respectively, at best response. Both initial pulmonary and lymphatic progressors (adjusted hazard ratios [95% confidence intervals], 6.37 [2.10–19.3], and 8.36 [2.16–32.4], respectively) were independently associated with survival regardless of intrahepatic response.ConclusionsThe response of metastatic HCC to the Atezo/Bev regimen may be used to determine whether to continue treatment or switch to second‐line treatment at an early phase of therapy.

Funder

National Research Foundation of Korea

Publisher

Wiley

Reference35 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3